

## **Medibio Successfully Completes First ilumen™ Pilot with Compass Group PLC**

### **Highlights:**

- The first of four planned ilumen™ pilots with Compass Group PLC has completed
- The program achieved a voluntary engagement rate of 65.3%
- Medibio is continuing to work with Compass with two further pilots having commenced in mid-October
- These pilot programs are providing invaluable insight to the Company as we work to further our relationship with the Compass Group

**Melbourne, Australia and Minneapolis, MN – 21 October 2019: Medibio Limited (MEB or the Company)(ASX: MEB)(OTCQB: MDBIF), a health technology company today provides a market update on the status of ilumen™ pilot programs with Compass Group PLC (Compass Group).**

Medibio is pleased to announce the successful completion of the first of four planned ilumen™ pilot programs with Compass Group. As part of the Health & Well-being element of its global 'Purpose' strategy, Compass Group implements various programs to support and improve the mental well-being and physical health of its workforce and its clients' workforce. ilumen™ fits into this strategy by providing participants with early screening for symptoms of depression, anxiety, and stress.

Under the terms of the contract ilumen™ was offered, on a voluntary basis, to personnel within the Business and Industry Division in the United Kingdom.

The Company is pleased to share the following update:

- Participants had access to the program over a four-week period commencing in mid-August.
- The program achieved a voluntary engagement rate of 65.3%.
- The results from the first pilot have been presented to Compass. The anonymised aggregated data, delivered through unique dashboard reporting, has offered insights to better support and manage the mental well-being of their workforce.
- Medibio continues to work with Compass Group with two additional pilot programs beginning in mid-October and the fourth pilot to commence in January.

"We are especially pleased with the engagement rate achieved in this initial program with Compass Group and look forward to delivering strong results moving forward," said Jennifer Solitario, Sr VP of Corporate Health. "This pilot and our productive meeting to share program results with Compass Management is providing invaluable insight to the Company as we work to further our relationship with the Compass Group."

# ASX Announcement

Medibio Limited – 21 October 2019



## About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcm Markets.com](http://www.otcm Markets.com) and [www.asx.com.au](http://www.asx.com.au).

<b>Further Information:</b>		Website: <a href="http://www.medibio.com.au">www.medibio.com.au</a>
<b>Medibio Media Enquiries:</b> Kristi Hamilton Director, Strategic Communications Medibio Limited <a href="mailto:kristi.hamilton@medibio.com.au">kristi.hamilton@medibio.com.au</a> T: +1 952 232 0934	<b>Australian Investor Enquiries:</b> Peter Taylor NWR Communications <a href="mailto:peter@nwrcommunications.com.au">peter@nwrcommunications.com.au</a> T: +61 (0) 412 036 231	